Virtech Bio

Executive Summary

VirTech Bio is an early-stage biotechnology company based in San Diego, developing OxyBridge, a proprietary human-derived hemoglobin-based oxygen carrier (HBOC) designed to address critical unmet needs in trauma and transplant medicine. The company's primary applications are for treating severe hemorrhagic shock in trauma patients and for ex vivo perfusion of donor organs prior to transplantation. By leveraging non-dilutive funding from the U.S. Department of Defense, VirTech Bio aims to advance its platform through preclinical and early clinical stages. Founded in 2020, the company is currently in Phase 1 development, with a focus on demonstrating safety and efficacy in initial trials. VirTech Bio's technology has the potential to significantly impact emergency medicine and organ transplantation by providing a stable, human-derived oxygen carrier that can be used in resource-limited settings. The company's reliance on DoD funding underscores the strategic importance of its technology for military and civilian trauma care. With its early-stage status, VirTech Bio faces typical development risks, including regulatory hurdles and clinical trial outcomes. However, the clear value proposition and existing government support provide a foundation for future growth. Upcoming catalysts include the initiation of Phase 1 trials, preclinical data presentations, and potential DoD contract expansions.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 1 clinical trial for OxyBridge in hemorrhagic shock70% success
• Q3 2026Presentation of preclinical data for ex vivo organ perfusion80% success
• Q4 2026Additional DoD contract award for OxyBridge development60% success